semaglutide nash phase 3 essence Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in three adults worldwide, yet many cases remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? Semaglutide shows powerful benefits for

SYMLIN has not been studied in patients with end-stage renal disease [see Clinical Pharmacology (12.3)]

For years, many of us have been moving earlier toward ablation because we see the benefit in practiceimproving symptoms and potentially preventing AF progression

It does not burn fat

Our practice has continued expanding its Peptide Therapy offerings over the past few years

This is a process where the liver breaks down substances before they can circulate through the rest of the body

Unlike subcutaneous fat that sits under your skin, visceral fat actively produces inflammatory compounds and contributes to metabolic dysfunction